Archives

by in
Entry Author Date Location
Opexa Tries a Personalized Cell Therapy Against Last, Worst Stage of MS 05/02/13 Texas
Acorda Stock Climbs on Post-Stroke Study 04/15/13 New York
Big Data Is BS in Healthcare. When Will It Become Real? 04/15/13 National
San Diego Life Sciences Roundup: Receptos IPO, Isis, Versant, & More 04/12/13 San Diego
East Coast Biotech Roundup: Biogen Idec, Third Rock, T2 Bio, Dart 03/29/13 Boston
Biogen Idec Wins FDA Approval For Oral Multiple Sclerosis Drug 03/27/13 Boston
Allozyne Conducts Round of Employee ‘Furloughs’ 03/15/13 Seattle
San Diego Life Sciences Roundup: Regulus, MEI Pharma, Qualcomm & More 08/16/12 San Diego
Biogen Idec, Regulus Cut Deal to Monitor Multiple Sclerosis 08/15/12 San Diego
Innovimmune Pursues Pharma Partners, Shuns VCs 08/07/12 New York
Genzyme, Epizyme, & Rib-X Among the Week’s Life Sciences Newsmakers 04/27/12 Boston
New Data on Genzyme MS Drug Shows Improvement in Disability 04/24/12 Boston
Five Questions: Acorda CEO Ron Cohen on the Future of Neurology R&D 04/17/12 New York
Provid Pharma Leans on MS Society’s Venture Fund to Boost Lead Drug 04/12/12 New York
How Biogen Idec Overhauled R&D Under Doug Williams 03/07/12 Boston
Transparency Launches as Linux of Drug Development 02/23/12 New York
Angry at the Genome 01/25/12 Boston
Allozyne “Redistributes” Workforce After Scrapping Poniard Merger Plan 01/03/12 Seattle
Allozyne Raises More VC Cash, Looks to FDA Meeting After Poniard Deal Fizzles 12/23/11 Seattle
Aileron Expands Roche Deal, Agios Gets $78M, Genzyme MS Drug Advances, & More Boston-Area Life Sciences News 11/18/11 Boston
Genzyme MS Drug Significantly Reduces Relapse, Disability in Late-Stage Trial 11/14/11 Boston
Today’s Xconomy Report: Biogen Idec Meets Goals in Clinical Trial, iRobot Layoffs, $1M Awarded by MassChallenge, and Bay State Venture Capital Earnings 10/28/11 Boston
New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News 10/28/11 Boston
Biogen Idec’s Oral Multiple Sclerosis Drug Passes 2nd Major Test; Stock Soars 10/26/11 Boston
Sha Mi, Biogen Idec’s Neurology Ace, to Join “The Genetics Institute Impact” on Dec. 14 10/21/11 Boston
Allozyne Looks to Rustle Up Interest on Wall Street With Backdoor IPO 07/13/11 Seattle
Coronado Biosciences Pulls in $25.8 Million 07/06/11 New York
Allozyne Acquires Poniard Pharmaceuticals, Finds Backdoor Route to NASDAQ 06/22/11 Seattle
Biogen Idec CEO on Move Back to Cambridge: “We’re Working on It” 06/16/11 Boston
Proteostasis Nabs Partnership, $20M Investment, from Elan To Pursue Neurology Drugs 05/25/11 Boston
Page 1 of 6 next page »

Xconomy Events Across the Network

The Napa Summit 2013: New Rules for Growth

San Francisco · 6/3/13

More Xconomy Events

Xconomy’s Most Popular

  1. Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)
  2. Nine Lessons for Innovators from a Nobel Prize-Winning Psychologist
  3. Xconomy Opens in Texas, Expanding Roundup of Innovation Across U.S.
  4. Life After PowerPoint: Prezi Zooms Ahead in Digital Storytelling
  5. Do You Need an Extended Warranty? Do the Math, Says SquareTrade

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.